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es were observed, but 15 patients (39%) had stable disease. 
A CA19-9 reduction of  1 20% after 2 cycles of Cap was docu-
mented in 6 patients (15%). Median time to progression was 
2.3 months (range 0.5–45.1) and median overall survival 
(since start of Cap treatment) was 7.6 months (range 0.7–
45.1). Predominant grade 2 and 3 toxicities (per patient anal-
ysis) were hand-foot syndrome 28% (13% grade 3); anemia 
23%; leg edema 15%; diarrhea 13%; nausea/vomiting 10%, 
and leukocytopenia 10%.  Conclusion: Single-agent Cap is a 
safe treatment option for Gem-pretreated patients with ad-
vanced PC. Further evaluation of Cap in controlled clinical 
trials of Gem-pretreated patients with advanced PC is rec-
ommended.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Advanced pancreatic cancer (PC) remains a disease 
with a very unfavorable prognosis of survival. In 2006, an 
estimated 33,730 new cases were diagnosed in the United 
States, with a nearly identical rate of 32,300 deaths from 
PC  [1] . Median survival time for patients with advanced 
PC without treatment ranges from 3 to 4 months, where-
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 Abstract 
 Objective: To date, no standard regimen for salvage chemo-
therapy after gemcitabine (Gem) failure has been defined 
for patients with advanced pancreatic cancer (PC). Oral 
capecitabine (Cap) has shown promising activity in first-line 
chemotherapy trials in PC patients.  Methods: Within a pro-
spective single-center study, Cap was offered to patients 
who had already received at least 1 previous treatment reg-
imen containing full-dose Gem (as a single agent, as part of 
a combination chemotherapy regimen or sequentially with-
in a chemoradiotherapy protocol). Cap was administered 
orally at a dose of 1,250 mg/m 2 twice daily for 14 days fol-
lowed by 7 days of rest. Study endpoints were objective tu-
mor response rate by imaging criteria (according to RECIST), 
carbohydrate antigen 19-9 (CA19-9) tumor marker response, 
time to progression, overall survival and toxicity.  Results: A 
median of 3 treatment cycles (range 1–36) was given to 39 
patients. After a median follow-up of 6.6 months, 27 patients 
were evaluable for response: no complete or partial respons-
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as in patients receiving chemotherapy with single-agent 
gemcitabine (Gem), median survival times between 4.9 
and 7.2 months have been reported  [2–4] . Single-agent 
Gem is still regarded as one of the standards of care in the 
first-line treatment of patients with locally advanced or 
metastatic PC  [2] . To date, only 2 randomized controlled 
trials have demonstrated a significant prolongation of 
survival with the use of Gem-based combination therapy 
with either erlotinib or capecitabine (Cap)  [5, 6] .
 The role of second-line treatment after failure of first-
line chemotherapy remains controversial in this disease. 
Preliminary results of a small randomized study compar-
ing best supportive care alone versus chemotherapy with 
5-fluorouracil, folinic acid and oxaliplatin plus best sup-
portive care after Gem failure showed a prolongation of 
median survival by about 2.6 months with chemotherapy 
(2.3 vs. 4.9 months)  [7] . These data correlate well with a 
recently published study that reported a median survival 
time of about 1.9 months after failure of first-line Gem in 
74 patients with PC (of whom 97% received no second-line 
treatment)  [8] . Several small phase II trials have also been 
performed in Gem-pretreated patients with advanced PC: 
these studies indicate a median survival time of 4.2–6.8 
months in patients who received therapy with various 
anti-cancer agents  [9–16] . The largest study, investigating 
the role of salvage chemotherapy in PC patients after Gem 
failure, was a randomized trial of over 400 patients. Treat-
ment consisted of either rubitecan (an oral topoisomerase 
I inhibitor) or the physicians’ best choice of treatment or 
care  [17] . In this phase III trial, more than 90% of the pa-
tients were resistant to prior chemotherapy and 70% were 
resistant to 2 or more prior regimens. There was no sig-
nificant difference in median survival between the 2 treat-
ment arms (rubitecan vs. best choice: 3.6 vs. 3.1 months).
 Cap (Xeloda  ; F. Hoffmann-La Roche Ltd., Basel, 
Switzerland) has shown single-agent activity in the front-
line treatment of patients with advanced PC and also a 
promising efficacy and safety profile in combination 
with Gem in the phase II setting  [18–20] . Two random-
ized phase III studies have subsequently compared the 
combination of Gem plus Cap with single-agent Gem: 
one trial conducted by Herrmann and coworkers  [21] 
used a 3-week regimen of Gem plus Cap and failed to 
show a significant survival benefit for the combination 
regimen (7.2 vs. 8.4 months, p = 0.234). In contrast, pre-
liminary results reported by Cunningham and colleagues 
 [6] showed a significant prolongation of median survival 
for the Gem plus Cap combination when given at a high-
er dose intensity in a 4-week treatment schedule (6.0 vs. 
7.4 months; p = 0.026).
 This current study evaluated the efficacy and safety of 
the oral fluoropyrimidine Cap as a single agent in Gem-
pretreated patients with locally advanced or metastatic 
PC. For this evaluation, data from Gem-pretreated pa-
tients receiving salvage chemotherapy with Cap at our 
department were collected prospectively. All patients in-
cluded had progressed after at least 1 full-dose Gem-con-
taining chemotherapy or chemoradiotherapy (CRT) reg-
imen.
 Patients and Methods 
 Study Design 
 Between August 2003 and February 2007, 39 patients with ad-
vanced, pretreated PC received Cap chemotherapy at the Depart-
ment of Internal Medicine III, University of Munich, Germany. 
All consecutive patients that received at least 1 dose of Cap during 
this time period were included in the analysis. Data from these 
patients were collected prospectively and patients gave informed 
consent to treatment and data collection for statistical analysis 
and publication.
 Patient Population 
 All patients eligible for Cap treatment had received at least 1 
previous treatment regimen containing full-dose Gem (either as 
single-agent or combination chemotherapy, or sequentially with-
in a CRT protocol) for the treatment of histologically confirmed 
advanced PC (stages III and IV). Patients who previously received 
low-dose Gem as a radiosensitizer only were not defined as ‘Gem 
pretreated’ and thus not eligible for this analysis. All patients had 
progressive disease on imaging after prior Gem-based therapy; 
each patient that received primary CRT for nonresectable, locally 
advanced PC progressed by developing distant metastases. Most 
of the patients undergoing primary CRT received Gem as a radio-
sensitizer followed by sequential full-dose Gem or Gem-contain-
ing chemotherapy. There was no predefined limit on the number 
of previous therapies. Cap was offered only to patients with a Kar-
nofsky performance status (KPS)  6 70%, a life expectancy  6 12 
weeks and with adequate hematological, hepatic and renal func-
tion. Women who were breastfeeding or pregnant were ineligible 
for treatment.
 Chemotherapy and Supportive Treatment 
 Chemotherapy with Cap was administered in an outpatient 
setting. Cap was given orally twice daily at a dose of 1,250 mg/m 2 
(for patients aged  6 65 years: 1,000 mg/m 2 ) for 14 consecutive days 
followed by 7 days of rest. Treatment cycles were repeated every 21 
days. If necessary, dose reductions of Cap were performed accord-
ing to clinical and laboratory parameters and according to the de-
cision of the treating physician. Chemotherapy was continued un-
til disease progression or unacceptable toxicity. No prophylactic 
antiemetic treatment was administered. For supportive treatment 
of the known thrombophilic diathesis that occurs in patients with 
metastatic PC undergoing chemotherapy  [22] , patients without a 
history of thrombosis or pulmonary embolism received – if no 
contraindications were obvious – a daily prophylactic dose of sub-
cutaneous low-molecular weight heparin.
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 Evaluation Criteria for Efficacy and Toxicity 
 Physical examination (including body weight), KPS, vital 
signs and blood analysis (hematology and serum chemistry) were 
performed on day 1 of each cycle. In patients with measurable 
disease, response to chemotherapy was evaluated with ultra-
sound, CT/MRI scans or a positron emission tomography-CT 
scan before treatment and after 2 or 3 cycles of chemotherapy (6 
or 9 weeks of treatment, respectively) according to the RECIST 
criteria  [23] . Additionally, serum tumor marker levels of carbohy-
drate antigen 19-9 (CA19-9) were analyzed on day 1 of every cycle. 
Reductions in CA19-9 levels of  1 20 and  1 50% in relation to base-
line were used for the determination of a biochemical treatment 
response  [24] .
 Time to progression (TTP) was defined as the time from start 
of Cap treatment to the date when progressive disease was first 
confirmed by imaging criteria. In patients where no confirmation 
of progressive disease by imaging was possible (e.g., clinical dis-
ease progression occurred before first staging scan), the date 
when clinical disease progression was observed and/or when Cap 
treatment was discontinued was used as time point for the calcu-
lation of TTP. Two definitions for analyzing survival time were 
applied: first, the overall survival (OS) from initial diagnosis of 
PC to death, and second, OS from the start of Cap treatment to 
death.
 Safety was monitored in all patients who received at least 1 
dose of Cap. Toxicity was assessed at the beginning of each cycle 
according to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events, version 3.0.
 Statistical Analysis 
 Study endpoints included objective tumor response by imag-
ing, CA19-9 tumor marker response, TTP, OS and toxicity. Base-
line patient characteristics and laboratory values were expressed 
as median values with ranges, and TTP and OS times were deter-
mined by the Kaplan-Meier method.
 Results 
 Patient Characteristics 
 In total, 39 patients with histologically confirmed ad-
vanced PC were included in this study. Baseline patient 
characteristics are summarized in  table 1 . At treatment 
initiation with Cap, nearly all patients had metastatic dis-
ease (97%), mainly involving the liver and lung. Pretreat-
ment CA19-9 serum tumor marker levels were elevated 
(defined as levels  1 37 U/ml) in 31 patients (80%); the me-
dian CA19-9 baseline level in these patients was 2,438 
U/ml (range 43–98,833). Regarding previous therapy, 12 
patients had initially undergone curative-intent surgery 
for resectable PC, 9 patients had received previous pri-
mary CRT for locally advanced PC and all patients had 
received prior chemotherapy with full-dose Gem. Seven-
teen patients (44%) had been treated with 2 or more pre-
vious regimens before Cap was started.
 Treatment and Toxicity 
 After a median follow-up of 6.6 months (range 0.7–
45.1), 8 patients are still alive, including 2 patients still on 
Cap. Chemotherapy with Cap was discontinued mainly 
due to disease progression (35 patients); 1 patient refused 
further chemotherapy, and in 1 patient, Cap was discon-
tinued due to toxicity (grade 3 nausea/vomiting). A total 
of 207 treatment cycles of Cap were administrated during 
the study, with a median 3 cycles per patient (range 1–36). 
Table 1. Baseline patient characteristics at study entry
Characteristic Patients (n = 39) %
Median age, years 63 (42–75)
Gender
Male 21 54
Female 18 46
Median time from diagnosis, months 9.0 (2.5–48.0)
Stage of disease
Locally advanced 1 3
Metastatic 38 97
Histology
Adenocarcinoma 37 95
Acinar cell carcinoma 2 5
Tumor grading
G1 2 5
G2 19 49
G3 18 46
Site of metastasis
Liver 31 79
Lung 9 23
Peritoneum 2 5
Bone 2 5
KPS
100% 3 8
90% 17 44
80% 17 44
70% 2 5
Median pretreatment CA 19-9, U/ml  2,438 (43–98,833)
Previous treatment
Whipple operation 12 31
Prior CRT 15 39
Adjuvant intent 6
Palliative intent 9
Prior systemic CT 32 82
Prior full-dose Gem 39 100
Previous treatment regimens (CRT, CT), n
1 22 56
2 13 33
≥3 4 10
Figures in parentheses are ranges.
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Dose reductions and/or temporary treatment interrup-
tions due to toxicity (mainly hand-foot syndrome and di-
arrhea) were performed in 11 patients (28%). Twenty pa-
tients (51%) received concomitant medication with daily 
doses of a low-dose low-molecular weight heparin (either 
therapeutic or prophylactic dosing). Of the 37 patients 
that discontinued systemic treatment with Cap, 21 pa-
tients (57%) subsequently received further chemother-
apy.
 All 39 patients were evaluable for toxicity. Hemato-
logical and nonhematological toxicity data are summa-
rized in  table 2 . Cap was generally well tolerated in our 
patient population. Hematological toxicity was generally 
mild (grade 1 or 2 severity); no grade 4 hematological 
toxicity was observed. Regarding the nonhematological 
toxicities, hand-foot syndrome (51% of patients), nausea/
vomiting (33%) and diarrhea (31%) occurred most fre-
quently. The main grade 3 toxicity observed in this study 
was hand-foot syndrome in 5 patients (13%), no patient 
experienced grade 4 hand-foot syndrome. Only 1 grade 4 
toxicity occurred in a patient who suffered from a cere-
bral ischemia during treatment with Cap. No treatment-
related deaths were observed.
 Response and Survival 
 Twenty-seven patients (69%) were evaluable for re-
sponse by imaging criteria ( table 3 ). One patient received 
only 1 cycle of Cap before changing treatment because of 
grade 3 nausea; no assessment of response was therefore 
possible. Two patients did not have measurable disease and 
a further 9 patients (23%) showed clinically rapid disease 
progression and did not undergo radiological evaluation 
and confirmation of progressive disease. No complete or 
partial remission was observed. Disease stabilization was 
achieved in 15 of the 39 patients analyzed, resulting in a 
disease control rate of 39%. One patient with a poorly dif-
ferentiated (G3) acinar cell carcinoma of the pancreas cor-
pus with multiple liver metastases experienced long-term 
( 1 45.1 months) disease stabilization by RECIST criteria. 
Additionally, a positron emission tomography-CT scan 
showed a nearly complete metabolic response of the liver 
lesions to treatment with Cap in this patient.
 Twenty-eight of 31 patients with elevated baseline 
CA19-9 levels were evaluated for a CA19-9 tumor marker 
response. A CA19-9 decline of  1 20% after 2 cycles of che-
motherapy (6 weeks) was observed in 6 patients (15%), 
and a decline in CA19-9 values by  1 50% was observed in 
3 patients (8%). All patients with a CA19-9 decline  1 20% 
showed stable disease on imaging.
 The estimated median TTP was 2.3 months (range 
0.5–45.1); the Kaplan-Meier plot for TTP is shown in  fig-
ure 1 . At the time of final analysis in May 2007, 31 patients 
had died. Median OS since the start of Cap treatment was 
estimated to be 7.6 months (range 0.7–45.1); the Kaplan-
Meier plot for OS is shown in  figure 2 . The median sur-
vival time calculated from initial diagnosis of PC to death 
was 19.2 months (range 4.2–60.4).
 Discussion 
 There is increasing evidence that selected patients 
with advanced PC may benefit from second-line chemo-
therapy after failure of first-line Gem or Gem-based 
Table 2. Hematological and nonhematological toxicity according 
to NCI-CTCAE (version 3.0)
Toxicity Patients (n = 39)
grade 1 grade 2 grade 3 grade 4
Leukocytopenia 9 (23) 4 (10) 0 0
Neutropenia 1 (3) 0 1 (3) 0
Thrombocytopenia 11 (28) 0 0 0
Anemia 13 (33) 8 (21) 1 (3) 0
Hand-foot syndrome 9 (23) 6 (15) 5 (13) 0
Diarrhea 7 (18) 5 (13) 0 0
Nausea/vomiting 9 (23) 2 (5) 2 (5) 0
Mucositis 8 (21) 1 (3) 0 0
Infection 0 2 (5) 1 (3) 0
Leg edema 0 6 (15) 0 0
Skin rash 0 3 (8) 0 0
Alopecia 1 (3) 0 0 0
Cerebral ischemia 0 0 0 1 (3)
Figures in parentheses are percentages. NCI-CTCAE = Na-
tional Cancer Institute Common Terminology Criteria for Ad-
verse Events.
Table 3. Response to treatment with Cap (RECIST criteria)
Response by imaging Patients (n = 39)
Evaluable patients 27 (69)
Partial response 0 (0)
Stable disease 15 (39)
Progressive disease 12 (31)
Disease control rate 15 (39)
Figures in parentheses are percentages.
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treatment regimens. Based on currently available data, a 
median survival time of about 1.9 to 2.3 months after fail-
ure of Gem can be expected without further chemother-
apy  [7, 8] . Several phase II trials using different treatment 
regimens suggest an improved median survival time 
(from the start of second-line chemotherapy) in the range 
of 4.2 to 6.8 months  [16] . Nevertheless, these results must 
still be regarded carefully, and it should be kept in mind 
that nonrandomized phase II trials often include a pos-
sible selection bias. The latest version of the National 
Comprehensive Cancer Network guidelines for pancre-
atic adenocarcinoma recommends a second-line chemo-
therapeutic treatment after failure of first-line Gem in 
selected patients using, for example, single-agent Cap or 
a FOLFOX (5-fluorouracil/leucovorin and oxaliplatin)-
like regimen  [25] . However, to date, no data from clinical 
trials using Cap monotherapy as salvage treatment after 
Gem failure are available. Only 2 groups reported results 
from second-line phase II trials using a combination reg-
imen of Cap plus erlotinib and Cap plus oxaliplatin, re-
spectively  [13, 26] .
 The prospective study data reported here demonstrate 
that single-agent Cap is a safe treatment option for this 
patient population. The toxicity data in Gem-pretreated 
patients did not show any marked differences compared 
with the first-line study published by Cartwright and col-
leagues  [18] that used the same Cap dose schedule as our 
study. However, the overall incidence of hand-foot syn-
drome in our patient population was 51%, with 5 patients 
(13%) experiencing grad 3 toxicity. Cartwright et al.  [18] 
reported an overall incidence of 52% for hand-foot syn-
drome in their first-line phase II study, with a grade 3 rate 
of 17%. As the patients’ quality of life may be significant-
ly affected by this clinically relevant toxicity, one might 
also consider a reduced dose of Cap (e.g., 1,000 mg/m 2 on 
days 1–14 every 3 weeks for all patients independent of 
their age) when used as a salvage monotherapy after Gem 
failure. If Cap is combined with a second drug, e.g., erlo-
tinib  [13] or oxaliplatin  [26] , in this setting, toxicity 
should also be regarded carefully; especially if the 2-drug 
regimen may result in an overlapping toxicity profile 
(like skin toxicity or diarrhea, respectively).
 Regarding efficacy, single-agent Cap produced a dis-
ease control rate of 39% with no objective responses. 
These data appear inferior compared with other phase II 
trials, mainly using oxaliplatin-based combination che-
motherapy, in the second-line setting  [12, 14, 15] . How-
ever, our study population might represent a group of pa-
tients with poor prognostic features (100% Gem-pretreat-
ed patients, 97% with metastatic disease, 49% with a KPS 
 ! 90% and 44% who had received 2 or more treatment 
regimens before study entry). Based on these baseline pa-
tient characteristics, a median TTP of 2.3 months (about 
10 weeks) and an OS of 7.6 months (about 32 weeks) from 
the start of Cap treatment appear similar to the results of 
phase II studies investigating combination chemothera-
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 Fig. 1. Estimated TTP (median 2.3 months, range 0.5–45.1).  Fig. 2. Estimated OS (median 7.6 months, range 0.7–45.1). 
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py in this patient population  [16] . Furthermore, prelimi-
nary results of a randomized second-line trial after Gem 
failure (comparing 5-fluorouracil/folinic acid vs. 5-fluo-
rouracil/folinic acid plus oxaliplatin) reported a median 
TTP of about 1.9 months (8 weeks) for the reference arm 
with 5-fluorouracil/folinic acid  [27] . However, interstudy 
comparisons of survival results can be difficult to per-
form correctly: patients may receive further treatment af-
ter failure of the study therapy (57% of patients received 
further chemotherapy after Cap failure in this study) and 
also because of differences in important patient prognos-
tic factors. The current study data are derived from a sin-
gle, high-volume German center. Therefore, it is likely 
that the survival results represent a ‘positive’ selection 
bias (also with regard to the observed median OS of 19.2 
months from first diagnosis of PC).
 This study also included 2 patients with the rare his-
tology of a pancreatic acinar cell carcinoma. These pa-
tients do not only have different histological features 
compared with patients with (ductal) adenocarcinoma, 
they also seem to have a different prognosis  [28, 29] . Both 
patients with metastatic acinar cell carcinoma in this 
study experienced prolonged disease control during 
treatment with Cap (TTP of 9.5 and  1 45.1 months, re-
spectively), and they showed a favorable survival progno-
sis with an OS (from initial diagnosis) of 60.4 and  1 48.1 
months, respectively.
 To date, it remains an unsolved and important clinical 
question which treatment should be offered to a patient 
with advanced PC who requests further chemotherapy 
after Gem failure. In our opinion, patients for second-line 
therapy should be selected carefully based on known 
prognostic factors for this disease  [8, 30] . For example, 
KPS may serve as a useful and convenient clinical tool. 
There is increasing evidence that pretreatment KPS is a 
useful prognostic factor in the first-line setting, and that 
it possibly also has the potential to select patients for dif-
ferent treatment strategies (e.g., single-agent vs. combi-
nation chemotherapy)  [21, 30] . More recently, KPS was 
identified as an independent prognostic factor for OS and 
progression-free survival in PC patients that failed prior 
Gem treatment  [8, 31] . Thus, a clinical investigation of 
these important issues regarding patient selection and 
treatment individualization is strongly recommended. 
Only well-designed, randomized, controlled clinical tri-
als will help to answer the current – and clinically ex-
tremely relevant – questions concerning the benefit of 
second-line chemotherapy. Based on the data reported 
here, and also with regard to the encouraging results 
from randomized trials in the first-line setting, Cap 
should be included in these investigations either as a sin-
gle agent or as part of a combination regimen  [13, 26, 
32] .
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